ストックスクリーナーアプリを入手
34.53
2.27%
0.765
アフターアワーズ：
34.59
0.06
+0.17%
前日終値:
$33.77
開ける：
$34.52
24時間の取引高:
2.22M
Relative Volume:
0.94
時価総額：
$5.74B
収益：
$1.48B
当期純損益:
$241.66M
株価収益率:
24.10
EPS:
1.4325
ネットキャッシュフロー:
$480.33M
1週間 パフォーマンス:
+3.51%
1か月 パフォーマンス:
+24.88%
6か月 パフォーマンス:
+14.11%
1年 パフォーマンス:
+27.89%
1日の値動き範囲:
$34.11
$34.72
1週間の範囲:
$32.76
$34.72
52週間の値動き範囲:
$25.16
$36.48
Alkermes Plc Stock (ALKS) Company Profile
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
34.53 | 5.74B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
(ALKS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Avadel Stock Rises After Acquisition Offer By Alkermes - MSN
Alkermes plc stock (IE00B56GVS15): Is its neuroscience focus strong enough to drive steady upside? - AD HOC NEWS
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting - BioSpace
Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation - MSN
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities - CSRwire
Alkermes (ALKS) Unveils Promising Data on Alixorexton for Narcol - GuruFocus
Alkermes to present narcolepsy drug data at neurology meeting - Investing.com
Alkermes to present narcolepsy drug data at neurology meeting By Investing.com - Investing.com Canada
Narcolepsy patients showed 13 weeks of gains in Alkermes study - Stock Titan
Robeco Institutional Asset Management B.V. Purchases 151,283 Shares of Alkermes plc $ALKS - MarketBeat
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes (ALKS) Reveals Positive Findings on Lybalvi for Schizop - GuruFocus
Alkermes publishes 56-week study on Lybalvi negative symptoms By Investing.com - Investing.com Australia
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry - BioSpace
Alkermes publishes 56-week study on Lybalvi negative symptoms - Investing.com
Schizophrenia study tracks symptom gains for 56 weeks on LYBALVI - Stock Titan
Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative? - simplywall.st
Alkermes (ALKS) director Nancy Lurker exercises RSUs, netting 13,555 shares - Stock Titan
Tudor Investment Corp ET AL Takes Position in Alkermes plc $ALKS - MarketBeat
ALKS (Alkermes) Cash Receipts from Operating Activities - GuruFocus
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF S - GuruFocus
Alkermes PLC (ALKS) Stock Down 4.5% but Still Overvalued -- GF Score: 79/100 - GuruFocus
Will Alkermes plc benefit from government policyEarnings Growth Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
B of A Securities Raises Price Target for ALKS to $36 | ALKS Sto - GuruFocus
Market Fear: Is Alkermes plc stock showing strong momentum2026 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn
How (ALKS) Movements Inform Risk Allocation Models - Stock Traders Daily
Alkermes PLC (ALKS) Stock Price Down 4.08% on Apr 7 - GuruFocus
RBC Capital Adjusts Price Target on Alkermes Public to $44 From $45, Maintains Outperform Rating - marketscreener.com
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
Alkermes (NASDAQ:ALKS) EVP Sells $70,315.38 in Stock - MarketBeat
Alkermes (ALKS) EVP David Gaffin sells 2,034 shares in 10b5-1 trade - Stock Titan
Alkermes (NASDAQ: ALKS) 2026 proxy outlines CEO change, $1.48B 2025 revenue and Avadel acquisition - Stock Titan
Alkermes plc (NASDAQ: ALKS) Form 144 lists affiliate sale amounts - Stock Titan
Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet? - simplywall.st
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program - CSRwire
Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton - Sleep Review
Alkermes plc (ALKS) stock price, news, quote and history - Yahoo Finance UK
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes stock hits 52-week high at $36.46 By Investing.com - Investing.com South Africa
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
1.84%
6.22%
大文字化:
|
ボリューム (24 時間):